

PUBLISHED BY  
THE MEDICAL RESEARCH SOCIETY AND THE BIOCHEMICAL SOCIETY

©The Medical Research Society and the Biochemical Society 1989  
ISSN 0143-5221

Printed in Great Britain by Whitstable Litho Ltd, Whitstable, Kent

# Clinical Science

## EDITORIAL BOARD

**Chairman**

M. J. Brown

**Deputy Chairmen**

N. J. Douglas

I. A. Macdonald

J. C. Atherton

G. Bianchi

R. F. Bing

I. T. Boyle

J. R. Bronk

J. A. Davies

K. E. Davies

P. L. Drury

K. N. Frayn

S. Freedman

R. W. Fuller

R. Hainsworth

H. J. Hodgson

M. Lockwood

C. J. Lote

G. D. O. Lowe

A. M. McGregor

D. J. Millward

M. J. Mulvany

P. L. Padfield

L. Poston

A. Shenkin

J. Shepherd

D. J. Sheridan

R. A. Stockley

J. A. Summerfield

T. Unger

M. Walser

R. Wilkinson

D. H. Williamson

## INFORMATION FOR AUTHORS AND SUBSCRIBERS

*Clinical Science* is published by the Medical Research Society and the Biochemical Society and distributed by the Biochemical Society. Two volumes of six parts, each of about 100 pages, are published each year.

**Subscriptions.** Orders should be placed with a bookseller or subscription agent, or sent to the Biochemical Society Book Depot, P.O. Box 32, Commerce Way, Colchester CO2 8HP, Essex, U.K. Subscription prices: £140.00 (U.K.), £140.00 (Overseas) and \$280.00 (North America) per annum, post free. Back issues: write to the Biochemical Society Book Depot (address above).

**Supplements to Clinical Science.** These are issued each year and are distributed free to subscribers. Supplements are proceedings of the Medical Research Society, and from time to time proceedings of international meetings in clinical and related biological sciences may also be published as Supplements. The Chairman of the Editorial Board welcomes suggestions for possible Supplements, for consideration by *Clinical Science*.

**Guidance for Authors.** Detailed guidance is published in the January issue of each year and separate copies of 'Guidance for Authors' may be obtained free of charge from the Editorial Manager.

Papers submitted for publication should be sent to the Editorial Manager, *Clinical Science*, 7 Warwick Court, London WC1R 5DP, U.K.

Typescripts of rejected papers will not be returned to authors unless a specific request for the return has been made at the time of submission.

**Copyright.** All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior permission from *Clinical Science*. Photocopies of articles may be made in the U.S.A. for personal or internal use, or for the personal or internal use of specific clients, on the condition that the stated per-copy fee is paid to the Copyright Clearance Center Inc. (29 Congress Street, Salem, MA 01970, U.S.A.) for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. The CCC code for this journal is 0143-5221/89/\$2.00 + 0.00.

## RAPID COMMUNICATIONS

A rapid publication facility for authors, **Rapid Communications**, is now available. A Rapid Communication should be completed work, not merely a preliminary report, and not exceed four printed pages (3000 words with appropriate deductions, at the rate of 1000 words/page, for Figures and Tables). An editorial decision will be provided rapidly, without reports. Publication will proceed after an edited typescript, but not proofs, has been seen by the authors. Rejection of a submitted Rapid Communication will not preclude its re-submission for review as a full paper. For further details see Guidance for Authors (*Clinical Science*, 76, iii).

London: © The Medical Research Society and the Biochemical Society 1989

## FORTHCOMING PAPERS

Editorial Review: Cardiovascular receptors and the coronary circulation

D. A. S. G. Mary

Somatostatin analogue improves survival in conscious cirrhotic rats subjected to gastrointestinal bleeding

R. Cerini *et al.*

Effect of the cyclo-oxygenase inhibitor fenbufen on muscle and liver protein metabolism, muscle glutamine and plasma insulin in endotoxaemic rats

M. M. Jepson and D. J. Millward

Urinary kallikrein excretion during potassium chloride infusion in potassium-adapted rats: effect of amiloride

L. F. O. Obika

Effects of the baroreceptor reflex system on atrial natriuretic factor secretion during volume expansion in dogs

K. Kohara *et al.*

Effects of plasma, tumour necrosis factor, endotoxin and dexamethasone on extracellular proteolysis by neutrophils from healthy subjects and patients with emphysema

D. Burnett *et al.*

Increase in proteinuria and reduction in number of anionic sites on the glomerular basement membrane in rabbits by infusion of human nephrotic plasma *in vivo*

A. H. Wilkinson *et al.*

Naloxone-reversible inhibition of gall-bladder mucosal fluid secretion in experimental cholecystitis in the cat by acetophan, an enkephalinase inhibitor

L. Jivegård *et al.*

Atrial natriuretic peptide-induced decreases for renal blood flow in man: implications for the natriuretic mechanism

W. M. T. Janssen *et al.*

Effect of insulin on glucose metabolism in skeletal muscle from septic and endotoxaemic rats

B. Leighton *et al.*

Coumarin and 7-hydroxycoumarin treatment of canine obstructive lymphoedema

K. R. Knight *et al.*

Effect of phosphate-buffered sucrose flush solution upon the initial phase of ischaemic acute renal failure in the rat

O. S. Ferwana *et al.*

Differential blood pressure and hormonal effects after glucose and xylose ingestion in chronic autonomic failure

C. J. Mathias *et al.*

Whole body protein turnover and resting metabolic rate in homozygous sickle cell disease

A. Badaloo *et al.*

Role of thromboxane A<sub>2</sub> as a mediator of platelet-activating factor-induced aggregation of human platelets

R. K. McCulloch *et al.*

Circadian rhythm of glomerular filtration rate in normal individuals

M. G. Koopman *et al.*

Exercise-mediated peripheral tissue and whole-body amino acid metabolism during intravenous feeding in normal man

J. D. Albert *et al.*

The 57 mm clearance probe: a non-invasive tool for measuring subcutaneous blood flow

P. M. Grenhalgh *et al.*

Diet-induced thermogenesis in patients with gastrointestinal cancer cachexia

P. M. T. Weston *et al.*

## CLINICAL SCIENCE

Vol. 76, No. 6

June 1989

### CONTENTS

#### Cardiac autonomic dysfunction in obese subjects

M. ROSSI, G. MARTI, L. RICORDI, G. FORNASARI, G. FINARDI, P. FRATINO and  
L. BERNARDI 567-572

#### A direct method for the diagnosis of human hepatic type 1b and type 1c glycogen-storage disease

I. D. WADDELL, R. HUME and A. BURCHELL 573-579

#### Effect of replacing glucose with lipid on the energy metabolism of newborn infants

J. E. E. VAN AERDE, P. J. J. SAUER, P. B. PENCHARZ, J. M. SMITH and P. R. SWYER 581-588

#### Enhancement of the pulmonary vasoconstriction reaction to alveolar hypoxia in systemic high blood pressure

M. D. GUZZI, M. BERTI, E. DORIA, C. FIORENTINI, C. GALLI, M. PEPI and  
G. TAMBORINI 589-594

#### Is polyamine synthesis involved in the proliferative response of the intestinal epithelium to urogastrone-epidermal growth factor?

R. A. GOODLAD, H. GREGORY and N. A. WRIGHT 595-598

#### Effect of nedocromil sodium on down-regulation of pulmonary $\beta$ -adrenoceptors

I. KIOMIS, D. UKENA and P. J. BARNES 599-602

#### Platelet efflux of noradrenaline in patients with type 1 diabetes mellitus

C. C. T. SMITH, A. P. WILSON, B. N. C. PRITCHARD and D. J. BETTERIDGE 603-607

#### Effects of pimobendan, a novel inotropic agent, on intracellular calcium and tension in isolated ferret ventricular muscle

J. A. LEE, J. C. RUEGG and D. G. ALLEN 609-618

#### Influence of age on glomerular binding of angiotensin II in normotensive and spontaneously hypertensive rats

E. A. MESSENGER, C. STONIER and G. M. ABER 619-623

#### Differential effect of high-dose naloxone on the plasma adrenaline response to the cold-pressor test

P. M. G. BOULOUX, E. NEWBOULD, R. CAUSON, L. PERRY, L. H. REES, G. M. BESSER  
and A. GROSSMAN 625-630

#### Correlation of blood pressure in normotensive and hypertensive individuals with platelet but not lymphocyte intracellular free calcium concentrations

K. PRITCHARD, A. E. G. RAINES, C. C. ASHLEY, L. M. CASTELL, V. SOMERS,  
C. OSBORN, J. G. G. LEDINGHAM and J. CONWAY 631-635

#### Effect of subnutrition on normalized muscle force and relaxation rate in human subjects using voluntary contractions

S. A. BRUCE, D. NEWTON and R. C. WOLEDGE 637-641

#### Availability of amino acids supplied by constant intravenous infusion of synthetic dipeptides in healthy man

S. ALBERS, J. WERNERMAN, P. STEHLE, E. VENNARS and P. FÜRST 643-648

#### Amiloride prevents the metabolic acidosis of a KCl load in nephrectomized rats

G. A. ALTENBERG, P. C. ARISTIMUÑO, C. E. AMORENA and A. C. TAQUINI 649-652

#### Mechanisms of the antinatriuretic action of physiological doses of angiotensin II in man

P. H. SEIDELIN, J. J. McMURRAY and A. D. STRUTHERS 653-658

#### Effect of parenteral nutrition on protein turnover in endotoxaemic rats

S. A. ASH and G. E. GRIFFIN 659-666

#### Haemodynamic responses to vasopressin in anaesthetized young and adult Brattleboro rats

L. F. O. OBIKA and J. F. LAYCOCK 667-671

#### Single-breath breath-holding estimate of pulmonary blood flow in man: comparison with direct Fick cardiac output

A. H. KENDRICK, A. ROZKOVEC, M. PAPOUCHADO, J. WEST and G. LASZLO 673-676

### CORRESPONDENCE SECTION

#### Effect of fluoride on parathyroid hormone

D. S. GILL, A. COUMAR and P. DANDONA 677-678

### AUTHOR INDEX

### SUBJECT INDEX

# Volume 76

## AUTHOR INDEX

- Aber, G.M. 619-623  
Acheson, D.W.K. 377-385  
Adams, P.H. 81-86  
Ader, J.L. 311-315  
Ahlquist, J.A.O. 463-467  
Albers, S. 643-648  
Allam, M. 249-254  
Allen, D.G. 609-618  
Altenberg, G.A. 649-652  
Ambrosio, G.B. 87-93  
Amorena, C.E. 649-652  
Anderson, J.V. 423-429  
Argiles, A. 547-552  
Aristimuño, P.C. 649-652  
Aronson, J.K. 397-402  
Asamoah, K.A. 137-141  
Ash, S. A. 659-666  
Ashley, C.C. 631-635  
Aursudkij, B. 479-485  
Axelrud-Cavadore, C. 547-552
- Baggio, G. 87-93  
Bais, R. 303-309  
Ball, C.E. 503-508  
Ball, M.J. 165-170  
Barbend, J.C. 183-187  
Barlow, J.W. 495-501  
Barnes, P.J. 479-485, 599-602  
Barr, S.M. 67-71  
Bassi, A. 87-93  
Bax, N.D.S. 503-508  
Beasley, R. 229-230  
Beattie, E.C. 9-11  
Beevers, D.G. 39-42  
Beilin, L.J. 195-198  
Belch, J.J.F. 183-187  
Bennet, W.M. 447-454  
Bennett, E.D. 269-276  
Benson, H.A. 323-328  
Bernardi, L. 567-572  
Bernheim, J. 469-474  
Berti, M. 589-594  
Besser, G.M. 625-630  
Betteridge, D.J. 603-607  
Blaschke, T.F. 283-287  
Blom, H.J. 43-49  
Bloom, S.R. 95-101, 423-429  
Bloxam, D.L. 59-65  
Boer, W.H. 539-545  
Boers, G.H.J. 43-49
- Boghossian, S. 269-276  
Bosch, R.J. 157-163  
Bouloux, P.M.G. 625-630  
Braganza, J.M. 377-385  
Brammar, W.J. 151-155  
Broadhead, G.D. 503-508  
Broughton Pipkin, F. 529-534  
Bruce, S.A. 637-641  
Burchell, A. 573-579  
Burns, E. 503-508  
Bush, A. 143-149  
Busst, C.M. 143-149  
Butters, L. 67-71
- Casado, S. 157-163  
Castell, L.M. 631-635  
Causon, R. 625-630  
Cavadore, J.C. 547-552  
Channer, K.S. 229-230  
Chessim, B. 269-276  
Christie, J.P. 503-508  
Chung, K.F. 479-485  
Clozel, J.-P. 249-254  
Coe, C.I. 487-494  
Connacher, A.A. 447-454  
Conway, J. 631-635  
Conyers, R.A.J. 303-309  
Coppack, S.W. 509-516  
Corrocher, R. 87-93  
Corry, D. B. 559-563  
Coumar, A. 677-678  
Coumaros, G. 31-37
- Dandona, P. 677-678  
Davies, M. 81-86  
De Vasconcelos, P.R.L. 205-211  
Dhamu, S. 221-228  
Diggle, P.J. 125-135  
Dorhout Mees, E.J. 539-545  
Doria, E. 589-594  
Dunlop, W. 125-135  
Dunn, C.J. 261-263, 535-538
- Earl, D.J. 323-328  
Egberg, N. 369-276  
Eichler, H.-G. 283-287  
Eichler, I. 283-287  
Eisenhofer, G. 171-182, 517-522
- Ellory, J.C. 419-422  
Endre, Z.H. 19-29  
Evans, T.W. 479-485
- Farndon, J.R. 289-296  
Ferguson, D.J.P. 19-29  
Ferrari, S. 87-93  
Fervenza, F.C. 419-422  
Finardi, G. 567-572  
Fiorentini, C. 589-594  
Firth, J.D. 1-8, 335-341, 387-395  
Fischli, W. 249-254  
Fisher, A.C. 183-187  
Fisher, T.C. 183-187  
Flynn, M.D. 231-236  
Fornasari, G. 567-572  
Forrest, J.B. 475-478  
Forrester, T. 199-203  
Franklyn, J.A. 463-467  
Fratino, P. 567-572  
Frayn, K.N. 323-328, 509-516  
Furman, B.L. 137-141  
Fürst, P. 643-648
- Gafter, U. 415-417  
Gahl, W.A. 43-49  
Galli, C. 589-594  
Gammage, M.D. 463-467  
Gibbons, A.J. 261-263  
Gibbons, G.F. 205-211  
Gill, G.S. 677-678  
Gill, J.R., Jr 517-522  
Glue, P. 397-402  
Goldstein, D.S. 171-182, 517-522  
Goodlad, R.A. 595-598  
Gorfien, J.B. 73-80  
Gorfien, S. 73-80  
Gosling, P. 39-42  
Graf, H. 265-268  
Grahame-Smith, D.G. 397-402  
Green, N.K. 463-467  
Greenhalgh, R.M. 221-228  
Gregory, H. 595-598  
Griffin, G.E. 659-666  
Grossman, A. 625-630  
Guarini, P. 87-93  
Guazzi, M.D. 363-368, 589-594

## Author Index

- Guerin, M. 553-557  
 Gupta, R.K. 565-566  
 Gylling, H. 297-301
- Halperin, M.L. 189-194  
 Hardee, M.M. 261-263  
 Hargreaves, M. 553-557  
 Harris, M. 125-135  
 Hartemann, D. 249-254  
 Harvey, C.M. 419-422  
 Hassan, A.A.K. 231-236  
 Hasunuma, K. 13-18  
 Heagerty, A.M. 565-566  
 Heath, M.F. 269-276  
 Heatley, R.V. 237-241  
 Hendry, B.M. 419-422  
 Hernando, N. 157-163  
 Herrera, E. 51-57  
 Heslop, K.E. 431-437  
 Hjemdal, P. 369-376  
 Hoffman, B.B. 283-287  
 Holgate, S.T. 229-230  
 Holness, M.J. 317-322  
 Honrath, U. 189-194  
 Hornstra, G. 369-376  
 Houston, B.J. 377-385  
 Hume, R. 573-579  
 Humphreys, S.M. 509-516  
 Humphries, S.E. 221-228  
 Hunt, L.P. 81-86, 377-385
- Imbs, J.-L. 31-37  
 Ito, K. 13-18
- Jamal, H. 95-101  
 James, M. 229-230  
 Jenkins, S.A. 243-247  
 Johannessen, A. 439-446  
 Johnson, A.W. 237-241  
 Johnson, C.S. 357-362  
 Johnston, I.D.A. 289-296  
 Jones, P.W. 277-282  
 Joyce, H. 487-494
- Kajetanowicz, A. 475-478  
 Karemaker, J.M. 523-528  
 Kariv, N. 469-474  
 Karwatowska-Prokopczuk, E. 255-260  
 Katsumata, H. 353-356  
 Keavey, P. 289-296  
 Keidan, A.J. 357-362  
 Kelleher, J. 237-241  
 Kendall-Taylor, P. 125-135  
 Kendrew, P.J. 195-198  
 Kendrick, H.H. 673-676
- Kettlewell, M.G. 205-211  
 Killar, L.M. 535-538  
 Kioumis, I. 599-602  
 Knight, W.B. 143-149  
 Koomans, A. 539-545  
 Kopin, I.J. 171-182  
 Krausz, T. 95-101  
 Krieger, J. 31-37  
 Kurtz, D. 31-37
- Lalor, B.C. 81-86  
 Lamb, G.A. 81-86  
 Laragh, J.H. 565-566  
 Larsson, P.T. 369-376  
 Laszlo, G. 673-676  
 Laycock, J.F. 667-671  
 Lazarus, N.R. 199-124  
 Ledingham, J.G.G. 1-8, 19-29, 335-341, 387-395, 631-635  
 Lee, D.B.N. 559-563  
 Lee, J.A. 609-618  
 Lee, R.M.K.W. 475-478  
 Lees, K.R. 67-71  
 Lehr, L. 31-37  
 Leivseth, G. 113-117  
 Leslie, R.D.G. 119-124  
 Levi, J. 415-417  
 Lewiston, N. 283-287  
 Lian, L.Y. 565-566  
 Lim, C.-F. 495-501  
 Lopez-Novoa, J. 157-163  
 Loveridge, N. 677-678  
 Lusowsky, M.S. 237-241  
 Lyall, F. 9-11
- Marti, G. 567-572  
 Marwah, S.S. 357-362  
 Mathias, C.J. 431-437  
 Mawer, E.B. 81-86  
 Maxwell, D.L. 423-429  
 May, C.N. 431-437  
 Mayer, G. 265-268  
 McMurray, J.J. 653-658  
 Meddings, J.B. 403-413  
 Meleagros, L. 95-101  
 Messenger, E.A. 619-623  
 Miettinen, T.A. 297-301  
 Mion, C. 547-552  
 Monsalve, M.V. 221-228  
 Morarji, Y. 59-65  
 Morgan, T.O. 553-557  
 Morrison, R. 529-534  
 Morton, J.J. 9-11  
 Morton, W. 475-478  
 Moruzzi, P. 363-368  
 Moss, R. 269-276  
 Mourad, G. 547-552  
 Munro, S.L. 495-501  
 Murdoch, A.P. 125-135
- Nakamoto, H. 353-356  
 Newbould, E. 625-630  
 Newton, D. 637-641  
 Nielsen, A.H. 439-446  
 Noble, B. 73-80  
 Nott, D.M. 243-247
- O'Brien, P.M.S. 529-534  
 Obika, L.F.O. 667-671  
 O'Donnell, A. 67-71  
 Ohishi, A. 353-356  
 Olivieri, O. 87-93  
 Olsson, G. 369-376  
 Opportuno, A. 87-93  
 Osborn, C. 631-635
- Pagnan, A. 87-93  
 Pai, G.R. 103-108, 109-112  
 Papouchado, M. 673-676  
 Pattinson-Green, P.M. 59-65  
 Payne, N.N. 423-429  
 Pencharz, P.B. 581-588  
 Pepi, M. 589-594  
 Perry, L. 625-630  
 Peruez, S. 95-101  
 Peters, T.J. 243-247  
 Piccolo, D. 87-93  
 Podjarny, E. 469-474  
 Polak, J.M. 95-101  
 Pomeranz, A. 469-474  
 Poulsen, K. 439-446  
 Powell, J.T. 221-228  
 Praddaude, F. 311-315  
 Preedy, V.R. 243-247  
 Prichard, B.N.C. 603-607  
 Pride, N.B. 487-494  
 Pritchard, K. 631-635
- Radda, G.K. 19-29  
 Raggatt, L.E. 495-501  
 Raine, A.E.G. 1-8, 335-341, 387-395, 631-635  
 Ratcliffe, P.J. 19-29  
 Rathaus, M. 469-474  
 Rathbone, B.J. 237-241  
 Rawles, J.M. 103-108, 109-112  
 Rees, L.H. 625-630  
 Reid, S.R. 103-108, 109-112  
 Reikevas, O. 113-117  
 Rennie, M.J. 447-454  
 Resnick, L.M. 565-566  
 Richard, K.A. 261-263  
 Ricordi, L. 567-572  
 Robb, D.A. 137-141  
 Rofe, A.M. 303-309  
 Rogers, D.F. 479-485  
 Rose, P. 377-385

- Rossi, M. 567-572  
 Rozkouec, A. 673-676  
 Rubin, P.C. 67-71  
 Ruegg, J.C. 609-618  
 Ruiz del Arbol, L. 51-57  
 Ruprai, A.K. 151-155
- Sakaguchi, H. 353-356  
 Salahudeen, A.K. 289-296  
 Samani, N.J. 151-155  
 Saphier, P.N. 677-678  
 Saruta, T. 353-356  
 Sauer, P.J.J. 581-588  
 Saunier, C. 249-254  
 Schmidt, M. 31-37  
 Schofield, P.S. 317-322  
 Scrimgeour, C.M. 447-454  
 Seidelin, P.H. 653-658  
 Sellars, L. 289-296  
 Seon, R. 199-203  
 Sforza, E. 31-37  
 Sganzerla, P. 363-368  
 Shapira, J. 469-474  
 Sheppard, M.C. 463-467  
 Shina, T. 13-18  
 Shinebourne, E.A. 143-149  
 Shvili, Y. 415-417  
 Simon, G. 329-333, 455-461  
 Slater, J.D.H. 423-427  
 Smith, C.C.T. 603-607  
 Smith, H.A. 323-328  
 Smith, J.M. 581-588  
 Smith, K. 447-454  
 Snow, R. 553-557  
 Somers, V. 631-635  
 Sonnenberg, H. 189-194  
 Sowter, M.C. 357-362  
 Spital, A. 213-219  
 Staite, N.D. 261-263  
 Stamp, T.C.B. 677-678  
 Stehle, P. 643-648  
 Sterns, R.H. 213-219
- Stewart, S.G. 59-65  
 Stockigt, J.R. 495-501  
 Stockley, R.A. 343-352  
 Stonier, C. 619-623  
 Struthers, A.D. 653-658  
 Stuart, J. 357-362  
 Stull, R. 517-522  
 Sturm, M. 195-198  
 Sugden, M.C. 317-322  
 Suzuki, H. 353-356  
 Swales, J.D. 151-155  
 Swyer, P.R. 581-588
- Talmi, Y.P. 415-417  
 Tamborini, G. 589-594  
 Tamura, Y. 13-18  
 Tange, J.D. 19-29  
 Tangerman, A. 43-49  
 Tapster, S. 289-296  
 Taquini, A.C. 649-652  
 Taylor, R.R. 195-198  
 Thomas, T.H. 289-296  
 Thum, J. 265-268  
 Tighe, D. 269-276  
 Tooke, J.E. 231-236  
 Topliss, D.J. 495-501  
 Torstensson, J. 113-117  
 Tran-Van, T. 311-315  
 Tuck, M.L. 559-563  
 Tucker, G.T. 503-508
- Ukena, D. 599-602
- Van Aerde, J.E.E. 581-588  
 Van den Elzen, J.P.A.M. 43-49  
 Van Lieshout, J.J. 523-528  
 Van Liew, J.B. 73-80  
 Vandongen, R. 195-198  
 Venkatesan, S. 243-247  
 Vergani, D. 119-124
- Vinnars, E. 643-648  
 Viswalingham, A. 397-402
- Waddell, I.D. 573-579  
 Waskett, R.J.D. 59-65  
 Watrin, A. 547-552  
 Watson, A. 487-494  
 Wennmalm, Å. 255-260  
 Wennmalm, M. 255-260  
 Wernerma, J. 643-648  
 Wesselling, K.H. 523-528  
 West, J. 673-676  
 Westergaard, H. 403-413  
 White, K. 165-170  
 White, M.C. 125-135  
 Whitehead, C.J. 431-437  
 Whyte, P.L. 323-328, 509-516  
 Wieling, W. 523-528  
 Wilkinson, R. 289-296  
 Williams, N.R. 59-65  
 Williamson, D.H. 205-211  
 Wilson, A.P. 603-607  
 Wilson, D.R. 189-194  
 Wilson, R.C. 277-282  
 Winter, R.J.D. 95-101  
 Wiseman, S.A. 211-228  
 Woledge, R.C. 637-641  
 Wood, A.J. 397-402  
 Woods, K.L. 565-566  
 Wright, N.A. 595-598  
 Wyatt, J.I. 237-241
- Yamada, K. 13-18  
 Yang, H. 475-478  
 Yates, J. 243-247  
 Yoshida, S. 13-18  
 Young, R. 221-228
- Zohar, Y. 415-417  
 Zorzano, A. 51-57

# Volume 76

## SUBJECT INDEX

First and last page numbers of papers to which entries refer are given. Page numbers marked with an asterisk refer to Editorial Reviews.

- $\beta$ -Adrenoceptor**  
vascular relaxation, cystic fibrosis 283–287
- $\beta$ -Adrenoceptor agonist**  
tachyphylaxis, nedocromil sodium 599–602
- Acid-base status**  
sodium/hydrogen exchange,  
hyperkalaemia 649–652
- Acute renal failure**  
regional hypoxia, erythrocytes 19–29
- Adenosine 5'-triphosphate**  
osteoarthritis, passive muscle stretching 113–117
- Adipose tissue**  
metabolic characteristics 509–516
- Adrenalectomy**  
morphine, hypertension 431–437  
potassium transport, medullary collecting  
duct 189–194
- Adrenaline**  
exercise, aminophylline 255–260  
platelet aggregation, filtralometry 369–376  
stress, naloxone 625–630
- Adrenocorticotrophin**  
stress, opioids 625–630
- Age**  
airway mechanics, smoking 487–494  
angiotensin II, glomerular receptors 619–623  
platelet-activating factor, lyso-derivative 195–198  
vasopressin, haemodynamic responses 667–671
- Aggregation**  
granulocytes 183–187
- Airway mechanics**  
smoking, age 487–494
- Airways**  
microvascular permeability, inflammatory  
mediators 479–485
- Albuminuria**  
blood pressure 39–42
- Alcohol dehydrogenase**  
liver disorders 51–57
- Aldehyde dehydrogenase**  
liver disorders 51–57
- Aldosterone**  
potassium adaptation 213–219  
potassium transport, medullary collecting  
duct 189–194  
pregnancy, prostacyclin 529–534  
sodium restriction, exertion 553–557
- Alkaline phosphatase**  
zinc status, iron supplementation 59–65
- Ambient temperature**  
forearm blood flow, glucose tolerance 323–328
- Amidarone**  
myosin heavy chains, messenger RNA 463–467
- Amiloride**  
acid-base status, hyperkalaemia 649–652
- Amino acid nutrition**  
dipeptide utilization 643–648
- Amino acid transport**  
erythrocytes, uraemia 419–422
- Amino acids**  
muscle protein synthesis 447–454
- Aminophylline**  
exercise, catecholamines 255–260
- Amyloidosis**  
 $\alpha$ - and  $\beta$ -microglobulin, haemodialysis 547–552
- Anaerobic threshold**  
renal anaemia, chronic haemodialysis 265–268
- Androgens**  
inactive plasma renin 439–446
- Angiotensin II**  
glomerular receptors, age 619–623  
ouabain-like factor, potassium transport 329–333  
pregnancy, prostacyclin 529–534  
prostanoid synthesis, sodium 469–474  
sodium excretion, lithium clearance 653–658
- Angiotensin converting enzyme**  
inhibitors, thiol group 353–356
- Anoxia**  
atrial natriuretic peptide, myocardium 95–101
- Antipyrine clearance**  
exocrine pancreatic disease, enzyme  
induction 377–385
- Apolipoprotein AI-CIII-AIV**  
DNA polymorphism, peripheral arterial  
disease 221–228
- Arginine vasopressin**  
urinary kallikrein–kinins, water diuresis 13–18
- Arithmetic test**  
pulmonary flow, venous return 363–368
- Aromatic benzaldehydes**  
oxygen affinity, sickle cell disease 357–362
- Arthritis**  
interleukin-1 535–538
- Ascorbic acid**  
gastric juice, gastritis 237–241

- Asthma**  
 β-adrenoceptor, nedocromil sodium 599–602
- Atrial fibrillation**  
 heart conduction system, vagus nerve 109–112
- Atrial natriuretic peptide**  
 hypercapnia, hypoxia 249–254  
 myocardium, anoxia 95–101  
 negative pressure breathing, natriuresis 423–429  
 obstructive sleep apnoea syndrome 31–37  
 receptor, calcium 9–11  
 renal effects 1–8\*
- Atrial pressure**  
 natriuresis, atrial natriuretic peptide 423–429
- Autonomic nervous system**  
 obesity, heart rate variability 567–572
- Bendroflumethiazide**  
 lithium and free water clearance 539–545
- Bile acid synthesis**  
 familial hypercholesterolaemia 297–301
- Blood flow**  
 ethanol, skeletal muscle 243–247
- Blood flow velocity**  
 capillaries, television microscopy 231–236
- Blood pressure**  
 albuminuria 39–42  
 angiotensin II glomerular binding, age 619–623  
 isolated sympathetic vasomotor failure 523–528  
 leucocytes, sodium 199–203  
 lymphocyte and platelet intracellular  
     calcium 631–635  
 pulmonary vasomotility, low oxygen  
     breathing 589–594
- Body temperature**  
 capillary blood flow, foot 231–236
- Brainstem auditory evoked response**  
 chronic renal failure 415–417
- Breath-holding**  
 pulmonary blood flow, cardiac output 673–676
- Breathlessness**  
 exercise, scaling 277–282
- Calcium**  
 atrial natriuretic peptide, receptor 9–11  
 lymphocytes, platelet, hypertension 631–635  
 platelets, hypertensive pregnancy 67–71
- Calcium metabolism**  
 fluoride 677–678
- Calcium metabolism disorder**  
 1,25-dihydroxycholecalciferol,  
     hyperparathyroidism 81–86
- Calcium sensitivity**  
 cardiac muscle, pimobendan 609–618
- Capillaries**  
 blood flow, television microscopy 231–236
- Capillary blood flow**  
 body temperature, posture 231–236
- Captopril**  
 chronic renal failure, hypertension 353–356  
 prostanoid synthesis, sodium 469–474
- Carbonic anhydrase inhibition**  
 lithium and free water clearance, thiazides 539–545
- Cardiac muscle**  
 calcium sensitivity, pimobendan 609–618
- Cardiac output**  
 breath-holding, pulmonary blood flow 673–676
- Carpal tunnel syndrome**  
 amyloidosis, haemodialysis 547–552
- Catecholamines**  
 forearm blood flow, ambient temperature 323–328  
 kidney, sympathetic nervous system 517–522  
 morphine, hypertension 431–437  
 stress, opioids 625–630
- Cation transport**  
 erythrocytes, dietary fat 87–93  
 erythrocytes, lithium 397–402
- Cell division**  
 epidermal growth factor, polyamines 595–598
- Cell proliferation**  
 epidermal growth factor, polyamines 595–598  
 muscular arteries, hypertension 475–478
- Chloroquine**  
 hypoglycaemia, diabetes 137–141
- Chlorothiazide**  
 lithium and free water clearance 539–545
- Cholesterol absorption**  
 familial hypercholesterolaemia 297–301
- Cholesterol synthesis**  
 familial hypercholesterolaemia 297–301
- Cholesterogenesis**  
 insulin, sepsis 205–211
- Chronic atrial fibrillation**  
 pindolol, digoxin 229–230
- Chronic inflammatory disease**  
 cytokines, ethylene vinyl acetate co-polymer 261–263
- Chronic renal failure**  
 angiotensin converting enzyme inhibitors, thiol group 353–356  
 brainstem auditory evoked response 415–417  
 sodium transport, endogenous digoxin-like immunoreactivity 157–163
- Chronic serum sickness**  
 proteinuria 73–80
- Cirrhosis**  
 alcohol and aldehyde dehydrogenases, ethanol metabolism 51–57
- Cold pressor test**  
 blood pressure, heart rate 523–528  
 pulmonary flow, venous return 363–368
- Cortisol**  
 stress, opioids 625–630
- Co-transport**  
 chronic renal failure, endogenous digoxin-like immunoreactivity 157–163
- Countertransport**  
 chronic renal failure, endogenous digoxin-like immunoreactivity 157–163
- Creatine phosphate**  
 osteoarthritis, passive muscle stretching 113–117

- Cysteine  
  chronic renal failure, hypertension 353–356
- Cystic fibrosis  
   $\beta$ -adrenoceptor, vascular relaxation 283–287
- Cytokines  
  ethylene vinyl acetate co-polymer, chronic inflammatory disease 261–263
- Deformability  
  erythrocytes, aromatic benzaldehydes 357–362
- Diabetes  
  events leading to 119–124\*
- noradrenaline efflux, platelets 603–607
- streptozotocin, chloroquine 137–141
- Diet  
  exertion, aldosterone 553–557
- magnesium, hypertension 565–566
- Dietary fat  
  cation transport, membrane lipid composition 87–93
- Diffusion barrier resistance  
  glucose transport, statistical analysis 403–413
- Digoxin  
  chronic atrial fibrillation, pindolol 229–230
- 1,25-Dihydroxycholecalciferol  
  hyperparathyroidism, 25-hydroxycholecalciferol 81–86
- Dihydroxyphenylalanine  
  dopamine, natriuresis 517–522
- Dihydroxyphenylglycol  
  neuronal re-uptake, noradrenaline 171–182
- Dipeptide utilization  
  parenteral nutrition 643–648
- DNA polymorphism  
  apolipoprotein AI–CIII–AIV, peripheral arterial disease 221–228
- DNA sequencing  
  respiratory disease 343–352\*
- Dopamine  
  dihydroxyphenylalanine, natriuresis 517–522
- Drug clearance  
  enzyme induction, exocrine pancreatic disease 377–385
- Dyspnoea  
  exercise, scaling 277–282
- Elastic arteries  
  muscle cell proliferation, hypertension 475–478
- Enalapril  
  chronic renal failure, hypertension 353–356
- Endogenous digoxin-like immunoreactivity  
  sodium transport, chronic renal failure 157–163
- Endotoxaemia  
  protein catabolism, parenteral nutrition 659–666
- Energy metabolism  
  glucose utilization, total parenteral nutrition 581–588
- Enzyme induction  
  exocrine pancreatic disease, xenobiotics 377–385
- Epidermal growth factor  
  cell division, polyamines 595–598
- Erythrocytes  
  cation transport, lithium 397–402
- cation transport, membrane lipid composition 87–93
- ethanol metabolism, aldehyde dehydrogenase 51–57
- lysine transport, uraemia 419–422
- magnesium, hypertension 565–566
- oxygen affinity, aromatic benzaldehydes 357–362
- renal hypoxic injury, morphology 19–29
- sodium transport, uraemia 559–563
- Ethanol metabolism  
  liver disorders 51–57
- Ethanol toxicity  
  blood flow, tissue RNA content 243–247
- Ethylene vinyl acetate co-polymer  
  cytokines, chronic inflammatory disease 261–263
- Exercise  
  breathlessness, perception 277–282
- catecholamines, aminophylline 255–260
- Exercise capacity  
  renal anaemia, chronic haemodialysis 265–268
- Exertion  
  sodium restriction, aldosterone 553–557
- Exocrine pancreatic disease  
  enzyme induction, drug clearance 377–385
- Extrarenal potassium homoeostasis  
  acid-base status, sodium/hydrogen exchange 649–652
- Familial hypercholesterolaemia  
  cholesterol absorption and synthesis 297–301
- Fatty acid synthesis  
  insulin, sepsis 205–211
- Fluoride  
  parathyroid hormone, calcium 677–678
- Foot  
  capillary blood flow, television microscopy 231–236
- Forearm blood flow  
  glucose tolerance, ambient temperature 323–328
- Free fatty acids  
  adipose tissue 509–516
- Free water clearance  
  thiazides, carbonic anhydrase inhibition 539–545
- Gastric juice  
  ascorbic acid, gastritis 237–241
- Gastrointestinal epithelium  
  epidermal growth factor, polyamines 595–598
- Gastrointestinal tract  
  blood flow, ethanol 243–247
- Gene duplication  
  renin gene, malignant hypertension 151–155
- Gene regulation  
  respiratory disease 343–352\*
- Glomerular filtration rate  
  1,25-dihydroxycholecalciferol, hyperparathyroidism 81–86

- Glomerular receptors**  
 angiotensin II, age 619–623
- Glomerulonephritis**  
 proteinuria 73–80
- Glucose**  
 adipose tissue 509–516
- Glucose-6-phosphatase**  
 glycogen-storage disease 573–579
- Glucose tolerance**  
 forearm blood flow, ambient temperature 323–328
- Glucose transport**  
 diffusion barrier resistance, statistical analysis 403–413
- Glucose utilization**  
 energy metabolism, total parenteral nutrition 581–588
- Glutamine**  
 parenteral nutrition, dipeptide utilization 643–648
- Glycated haemoglobin**  
 chloroquine, diabetes 137–141
- Glycerol**  
 adipose tissue 509–516
- Glycogen**  
 lipid synthesis, partial hepatectomy 317–322  
 osteoarthritis, passive muscle stretching 113–117
- Glycogenesis**  
 diagnosis, glucose-6-phosphatase 573–579
- Glycogen-storage disease**  
 diagnosis, glucose-6-phosphatase 573–579
- Glycollate**  
 oxalate, glycollate oxidase 303–309
- Glycollate oxidase**  
 oxalate, urolithiasis 303–309
- Granulocytes**  
 aggregation 183–187
- Graphical analysis**  
 glucose transport, diffusion barrier resistance 403–413
- Guanosine 3':5'-cyclic monophosphate**  
 obstructive sleep apnoea syndrome, nasal continuous positive airway pressure 31–37
- Haemodialysis**  
 amyloidosis,  $\alpha$ - and  $\beta$ -microglobulin 547–552  
 sodium transport, endogenous digoxin-like immunoreactivity 157–163
- Haemodynamic responses**  
 vasopressin, age 667–671
- Haemoglobin**  
 exercise capacity, resting haemodynamic parameters 265–268
- Handgrip test**  
 blood pressure, heart rate 523–528
- Heart conduction system**  
 atrial fibrillation, vagus nerve 109–112  
 sinus arrhythmia, vagus nerve 103–108
- Heart rate**  
 isolated sympathetic vasomotor failure 523–528
- Heart rate variability**  
 obesity, autonomic nervous system 567–572
- Hepatic extraction ratio**  
 Indocyanine Green 503–508
- Hepatitis**  
 alcohol and aldehyde dehydrogenases, ethanol metabolism 51–57
- Hepatocytes**  
 oxalate, glycollate oxidase 303–309
- Histamine**  
 airways, microvascular permeability 479–485
- 25-Hydroxycholecalciferol**  
 hyperparathyroidism, 1,25-dihydroxycholecalciferol 81–86
- Hydroxymethylglutaryl-coenzyme A**  
 fatty acid synthesis, insulin 205–211
- Hypercapnia**  
 atrial natriuretic peptide, plasma renin activity 249–254
- Hyperkalaemia**  
 acid-base status, sodium/hydrogen exchange 649–652
- Hyperparathyroidism**  
 1,25-dihydroxycholecalciferol, 25-hydroxycholecalciferol 81–86  
 hypertension, parathyroidectomy 289–296  
 renal dysfunction, parathyroidectomy 289–296
- Hypertension**  
 angiotensin II glomerular binding, age 619–623  
 cell proliferation, muscular arteries 475–478  
 chronic renal failure, angiotensin converting enzyme inhibitors 353–356  
 hyperparathyroidism, parathyroidectomy 289–296  
 intracellular sodium 455–461\*  
 lymphocyte and platelet intracellular calcium 631–635  
 magnesium, erythrocytes 565–566  
 morphine, catecholamines 431–437  
 platelet calcium, pregnancy 67–71  
 potassium transport, ouabain-like factor 329–333  
 pulmonary vasomotility, low oxygen breathing 589–594  
 renal and urinary kallikrein 311–315  
 sodium, leucocytes 199–203  
 sodium and lithium handling, isolated perfused kidney 335–341
- Hypoglycaemia**  
 chloroquine, diabetes 137–141
- Hypoxia**  
 atrial natriuretic peptide, plasma renin activity 249–254
- Immune complex disease**  
 proteinuria 73–80
- Immunoreactive insulin**  
 chloroquine, diabetes 137–141
- Inactive plasma renin**  
 androgens 439–446
- Indocyanine Green**  
 hepatic extraction ratio 503–508
- Inotropic agents**  
 cardiac muscle, intracellular calcium 609–618

- Insulin**  
 fatty acid synthesis, sepsis 205–211  
 forearm blood flow, ambient temperature 323–328
- $\gamma$ -Interferon**  
 ethylene vinyl acetate co-polymer, chronic inflammatory disease 261–263
- Interleukin-1**  
 arthritis 535–538  
 ethylene vinyl acetate co-polymer, chronic inflammatory disease 261–263
- Interleukin-2**  
 ethylene vinyl acetate co-polymer, chronic inflammatory disease 261–263
- Intestine**  
 glucose transport, statistical analysis 403–413
- Intracellular calcium**  
 cardiac muscle, inotropic agents 609–618
- Intravenous lipid**  
 metabolic effects 165–170
- Iron supplementation**  
 zinc status, pregnancy 59–65
- Isolated perfused kidney**  
 nephrotic syndrome, sodium handling 387–395  
 sodium and lithium handling, hypertension 335–341
- Isolated sympathetic vasomotor failure**  
 blood pressure, heart rate 523–528
- Isoprenaline**  
 $\beta$ -adrenoceptor, cystic fibrosis 283–287
- Kallikrein**  
 kidney, hypertension 311–315
- Kallikrein–kinin excretion**  
 arginine vasopressin, water diuresis 13–18
- Kallikrein–kinin system**  
 hypertension, kidney 311–315
- 2-Keto-4-methylthiobutyrate**  
 transamination of methionine, methionine adenosyltransferase deficiency 43–49
- Kidney**  
 atrial natriuretic peptide 1–8\*  
 catecholamines, sympathetic nervous system 517–522  
 kallikrein, hypertension 311–315  
 regional hypoxia, erythrocytes 19–29
- Lactate**  
 adipose tissue 509–516
- Lactate dehydrogenase**  
 oxalate, urolithiasis 303–309
- Leucine**  
 muscle protein synthesis, amino acids 447–454
- Leucocytes**  
 sodium, blood pressure 199–203  
 zinc, iron supplementation 59–65
- Leukotriene D<sub>4</sub>**  
 airways, microvascular permeability 479–485
- Lipid synthesis**  
 glycogen, partial hepatectomy 317–322
- Lipogenesis**  
 energy metabolism, total parenteral nutrition 581–588
- Lithium**  
 cation transport, erythrocytes 397–402  
 hypertension, isolated perfused kidney 335–341
- Lithium clearance**  
 angiotensin II 653–658  
 thiazides, carbonic anhydrase inhibition 539–545
- Liver**  
 glycogen, lipid synthesis 317–322
- Low oxygen breathing**  
 pulmonary vasomotor, hypertension 589–594
- Lung disease**  
 molecular biological techniques 343–352\*
- Luteinizing hormone**  
 pulses 125–135
- Lymphocytes**  
 intracellular calcium, hypertension 631–635
- Lysine transport**  
 erythrocytes, uraemia 419–422
- Lyso-platelet-activating factor**  
 age 195–198
- Magnesium**  
 erythrocytes, hypertension 565–566
- Malignant hypertension**  
 gene duplication, renin gene 151–155
- Maternal iron status**  
 zinc 59–65
- Maximum oxygen uptake**  
 renal anaemia, chronic haemodialysis 265–268
- Medium-chain triacylglycerols**  
 metabolic effects 165–170
- Medullary collecting duct**  
 potassium transport, aldosterone 189–194
- Membrane lipid composition**  
 erythrocytes, dietary fat 87–93
- Membrane transport**  
 lysine, erythrocytes 419–422
- Mental stress**  
 blood pressure, heart rate 523–528  
 platelet aggregation, filtragometry 369–376
- Messenger RNA**  
 myosin heavy chains, amidarone 463–467
- Methanethiol**  
 transamination of methionine, methionine adenosyltransferase deficiency 43–49
- Methionine**  
 transamination, methionine adenosyltransferase deficiency 43–49
- Methionine adenosyltransferase deficiency**  
 transamination of methionine 43–49
- 3-Methylthiopropionate**  
 transamination of methionine, methionine adenosyltransferase deficiency 43–49
- Microcatheterization**  
 potassium transport, medullary collecting duct 189–194

- $\alpha$ -Microglobulin**  
amyloidosis, haemodialysis 547–552
- $\beta$ -Microglobulin**  
amyloidosis, haemodialysis 547–552
- Microvascular permeability**  
airways, inflammatory mediators 479–485
- Molecular biological techniques**  
respiratory disease 343–352\*
- Morphine**  
hypertension, catecholamines 431–437
- Multi-organ damage**  
peritonitis 269–276
- Muscle cell proliferation**  
elastic arteries, hypertension 475–478
- Muscle fibres**  
osteoarthritis, passive muscle stretching 113–117
- Muscle function**  
subnutrition 637–641
- Muscle protein synthesis**  
amino acids 447–454
- Muscular arteries**  
cell proliferation, hypertension 475–478
- Myocardium**  
atrial natriuretic peptide, anoxia 95–101
- Myosin heavy chains**  
messenger RNA, amidarone 463–467
- Naloxone**  
stress, adrenaline 625–630
- Nasal continuous positive airway pressure**  
obstructive sleep apnoea syndrome, guanosine 3':5'-cyclic monophosphate 31–37
- Natriuresis**  
dopamine, dihydroxyphenylalanine 517–522  
negative pressure breathing, atrial natriuretic peptide 423–429
- Nedocromil sodium**  
 $\beta$ -adrenoceptor agonist, tachyphylaxis 599–602
- Negative pressure breathing**  
natriuresis, atrial natriuretic peptide 423–429
- Nephrectomy**  
brainstem auditory evoked response 415–417
- Nephrotic syndrome**  
isolated perfused kidney, sodium handling 387–395
- Neuronal re-uptake**  
noradrenaline, dihydroxyphenylglycol 171–182
- Neutrophil adhesiveness**  
peritonitis 269–276
- Nitrates**  
ascorbic acid, gastric carcinoma 237–241
- Nitrites**  
ascorbic acid, gastric carcinoma 237–241
- N*-Nitroamines**  
ascorbic acid, gastric carcinoma 237–241
- Non-linear regression**  
glucose transport, diffusion barrier resistance 403–413
- Noradrenaline**  
exercise, aminophylline 255–260  
neuronal re-uptake, dihydroxyphenylglycol 171–182  
stress, opioids 625–630
- Noradrenaline efflux**  
platelets, diabetes mellitus 603–607
- Normalized muscle force**  
subnutrition 637–641
- Normalized muscle relaxation rate**  
subnutrition 637–641
- Nuclear magnetic resonance**  
magnesium, erythrocytes 565–566
- Nuclear occupancy**  
thyroid hormone analogue 495–501
- Obesity**  
automatic nervous system, heart rate variability 567–572
- Obstructive sleep apnoea syndrome**  
guanosine 3':5'-cyclic monophosphate, nasal continuous positive airway pressure 31–37
- Opioids**  
stress, catecholamines 625–630
- Ornithine decarboxylase**  
cell proliferation, epidermal growth factor 595–598
- Osteoarthritis**  
passive muscle stretching 113–117
- Ouabain-like factor**  
potassium transport, vascular muscle 329–333
- Oxalate**  
glycollate oxidase, urolithiasis 303–309  
lactate dehydrogenase, urolithiasis 303–309
- Oxygen affinity**  
sickle cell disease, aromatic benzaldehydes 357–362
- Oxygen saturation**  
forearm blood flow, ambient temperature 323–328
- Parathyroid hormone**  
fluoride 677–678
- Parathyroidectomy**  
hypertension, hyperparathyroidism 289–296  
renal dysfunction, hyperparathyroidism 289–296
- Parenteral nutrition**  
dipeptide utilization 643–648  
protein catabolism, endotoxaemia 659–666
- Partial hepatectomy**  
glycogen, lipid synthesis 317–322
- Passive muscle stretching**  
osteoarthritis 113–117
- Perception**  
breathlessness, exercise 277–282
- Perfused rat kidney**  
regional hypoxia, erythrocytes 19–29
- Peripheral arterial disease**  
apolipoprotein AI–CIII–AIV, DNA polymorphism 211–228
- Peritonitis**  
multi-organ damage, phospholipase A 269–276

- Phosphodiesterase inhibition  
  cardiac muscle, pimobendan 609–618
- Phospholipase A  
  peritonitis, histological change 269–276
- Pimobendan  
  intracellular calcium, phosphodiesterase inhibition 609–618
- Pindolol  
  chronic atrial fibrillation, digoxin 229–230
- Plasma renin activity  
  hypercapnia, hypoxia 249–254  
  renin gene, malignant hypertension 151–155
- Platelet aggregation  
  mental stress, adrenaline 369–376
- Platelet-activating factor  
  airways, microvascular permeability 479–485  
  lyso-derivative, age 195–198
- Platelets  
  calcium, hypertensive pregnancy 67–71  
  intracellular calcium, hypertension 631–635  
  noradrenaline efflux, diabetes mellitus 603–607
- Polyamines  
  cell division, epidermal growth factor 595–598
- Posture  
  capillary blood flow, foot 231–236
- Potassium adaptation  
  aldosterone 213–219
- Potassium balance  
  medullary collecting duct, aldosterone 189–194
- Potassium chloride infusion  
  potassium transport, medullary collecting duct 189–194
- Potassium metabolism  
  acid-base status, sodium/hydrogen exchange 649–652
- Potassium transport  
  medullary collecting duct, aldosterone 189–194  
  ouabain-like factor, vascular muscle 329–333
- Pre-eclampsia  
  calcium, platelets 67–71  
  leucocyte, sodium 199–203
- Pregnancy  
  angiotensin II, prostacyclin 529–534  
  platelet calcium, hypertension 67–71  
  zinc status, iron supplementation 59–65
- Pregnancy-induced hypertension  
  calcium, platelets 67–71
- Pressure-natriuresis  
  isolated perfused kidney 335–341
- Prostacyclin  
  angiotensin II, sodium 469–474  
  pregnancy, angiotensin II 529–534
- Prostaglandin E  
  angiotensin II, sodium 469–474
- Prostaglandin F  
  angiotensin II, sodium 469–474
- Prostaglandins  
  pulmonary circulation, vasoconstriction 143–149
- Protein catabolism  
  parenteral nutrition, endotoxaemia 659–666
- Protein turnover  
  skeletal muscle, amino acids 447–454
- Proteinuria  
  angiotensin converting enzyme inhibitors, thiol group 353–356  
  immune complex disease 73–80
- Proximal tubule  
  sodium reabsorption, angiotensin II 653–658
- Pulmonary circulation  
  breath-holding, cardiac output 673–676  
  prostaglandins 143–149
- Pulmonary flow  
  sympathetic nervous system, venous return 363–368
- Pulmonary gas exchange  
  prostaglandins 143–149
- Pulmonary vasomotility  
  low oxygen breathing, hypertension 589–594
- Pulses  
  luteinizing hormone 125–135
- Puromycin aminonucleoside  
  isolated perfused kidney, sodium handling 387–395
- Receptor  
  atrial natriuretic peptide, calcium 9–11
- Regional hypoxia  
  kidney, erythrocytes 19–29
- Renal anaemia  
  exercise capacity, resting haemodynamic parameters 265–268
- Renal dysfunction  
  hyperparathyroidism, parathyroidectomy 289–296
- Renin  
  androgens 439–446  
  pregnancy, prostacyclin 529–534  
  sodium restriction, exertion 553–557
- Renin gene  
  gene duplication, malignant hypertension 151–155
- Renin–aldosterone system  
  negative pressure breathing, atrial natriuretic peptide 423–429
- Respiratory disease  
  molecular biological techniques 343–352\*
- Resting haemodynamic parameters  
  renal anaemia, chronic haemodialysis 265–268
- Scaling  
  breathlessness, exercise 277–282
- Sepsis  
  fatty acid synthesis, insulin 205–211
- Serum binding  
  thyroid hormone analogue 495–501
- Sickle cell disease  
  oxygen affinity, aromatic benzaldehydes 357–362
- Sinus arrhythmia  
  heart conduction system, vagus nerve 103–108
- Skeletal muscle  
  blood flow, ethanol 243–247
- Smoking  
  airway mechanics, age 487–494

- Sodium**  
 hypertension 455–461\*  
 hypertension, isolated perfused kidney 335–341  
 leucocytes, blood pressure 199–203  
 prostanoid synthesis, angiotensin II 469–474
- Sodium excretion**  
 angiotensin II 653–658
- Sodium handling**  
 isolated perfused kidney, nephrotic syndrome 387–395
- Sodium/hydrogen exchange**  
 acid-base status, hyperkalaemia 649–652
- Sodium–potassium pump**  
 ouabain-like factor, vascular muscle 329–333
- Sodium pump**  
 endogenous digoxin-like immunoreactivity, chronic renal failure 157–163
- Sodium restriction**  
 exertion, aldosterone 553–557
- Sodium transport**  
 endogenous digoxin-like immunoreactivity, chronic renal failure 157–163  
 erythrocytes, uraemia 559–563
- Spectral analysis**  
 heart rate variability, obesity 567–572
- Steatosis**  
 alcohol and aldehyde dehydrogenases, ethanol metabolism 51–57
- Stomach**  
 ascorbic acid, gastric juice 237–241
- Streptozotocin**  
 diabetes, chloroquine 137–141
- Stress**  
 naloxone, adrenaline 625–630
- Subnutrition**  
 muscle function 637–641
- Surgery**  
 glycogen, lipid synthesis 317–322
- Sympathetic nervous system**  
 catecholamines, kidney 517–522  
 noradrenaline, neuronal re-uptake 171–182  
 pulmonary flow, venous return 363–368
- Tachyphylaxis**  
 $\beta$ -adrenoceptor agonist, nedocromil sodium 599–602
- Television microscopy**  
 capillary blood flow, foot 231–236
- Theophylline clearance**  
 exocrine pancreatic disease, enzyme induction 377–385
- Thiazides**  
 lithium clearance, carbonic anhydrase inhibition 539–545
- Thiol group**  
 angiotensin converting enzyme inhibitors, chronic renal failure 353–356
- Thromboxane**  
 angiotensin II, sodium 469–474
- Thyroid hormone analogue**  
 nuclear occupancy, serum binding 495–501
- Tissue culture**  
 vascular muscle, ouabain-like factor 329–333
- Total parenteral nutrition**  
 cell proliferation, polyamines 595–598  
 energy metabolism, glucose utilization 581–588
- Transamination**  
 methionine, methionine adenosyltransferase deficiency 43–49
- Tyrosine**  
 parenteral nutrition, dipeptide utilization 643–648
- Uptake-1**  
 noradrenaline, dihydroxyphenylglycol 171–182
- Uraemia**  
 lysine transport, erythrocytes 419–422  
 potassium transport, ouabain-like factor 329–333  
 sodium transport, erythrocytes 559–563
- Urogastrone**  
 cell division, polyamines 595–598
- Urolithiasis**  
 oxalate, glycollate oxidase 303–309
- Vagus nerve**  
 atrial fibrillation, heart conduction system 109–112  
 heart conduction system, sinus arrhythmia 103–108
- Valsalva manoeuvre**  
 blood pressure, heart rate 523–528
- Vascular muscle**  
 potassium transport, ouabain-like factor 329–333
- Vascular relaxation**  
 $\beta$ -adrenoceptor, cystic fibrosis 283–287
- Vasoconstriction**  
 prostaglandins 143–149
- Vasopressin**  
 haemodynamic responses, age 667–671
- Vein**  
 $\beta$ -adrenoceptor, cystic fibrosis 283–287
- Venous return**  
 pulmonary flow, sympathetic nervous system 363–368
- Verapamil**  
 chronic atrial fibrillation, pindolol 229–230
- Water diuresis**  
 kallikrein-kinins, arginine vasopressin 13–18
- Xenobiotics**  
 enzyme induction, exocrine pancreatic disease 377–385
- Zinc status**  
 pregnancy, iron supplementation 59–65